Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Biotechnology

Healthcare
$0.31 -0.58%

-$0.00 today

Market cap
$69.95M
Beta
2.82
P/E (TTM)
-1.3
EPS (TTM)
-$0.54
52W Low $0.53High $2.35

Volume 2.77M

Average 3.79M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$68.26M

FY 2025 · Annual

Investing Cash Flow

$56.08M

FY 2025 · Annual

+4858.7% YoY

Financing Cash Flow

$108.41M

FY 2025 · Annual

+127.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(72.72M)(123.67M)(124.08M)(111.13M)(90.6M)
Depreciation & Amortization2.96M6.47M8.69M8.47M8.85M
Deferred Income Tax00000
Stock-Based Compensation2.95M11.47M15.31M16.5M13.05M
Change in Working Capital4.74M(849K)(5.65M)(7.93M)(2.46M)
Accounts Receivables00000
Inventory00000
Accounts Payables8.6M1.66M(3.28M)(581K)(1.43M)
Other Working Capital(3.86M)(2.51M)(2.37M)(7.35M)(1.03M)
Other Non-Cash Items1.26M2.16M3.66M3.59M2.9M
Operating Cash Flow(60.81M)(104.42M)(102.07M)(90.5M)(68.26M)
Capital Expenditures(25.12M)(20.63M)(1.24M)(1.03M)(618K)
Acquisitions (Net)00000
Purchases of Investments(213.44M)(140.48M)(56.64M)(87.07M)0
Sales of Investments0244.75M106.62M89.21M56.7M
Other Investing Activities08K(25K)17K0
Investing Cash Flow(238.56M)83.65M48.72M1.13M56.08M
Debt Repayment00000
Common Stock Issued188.54M77.39M3.87M46.76M108.41M
Common Stock Repurchased(13K)0000
Dividends Paid00000
Other Financing Activities461K380K181K987K0
Financing Cash Flow208.97M77.77M4.05M47.75M108.41M
Effect of Forex Changes00000
Net Change in Cash(90.41M)57M(49.31M)(41.62M)96.22M
Free Cash Flow(85.93M)(125.05M)(103.31M)(91.53M)(68.88M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$90.6M
+ D&A$8.8M
+ Stock-Based Comp$13.0M
+ Deferred Tax$0
- Working Capital-$2.5M
+ Other Non-Cash$2.9M
= Operating Cash Flow-$68.3M
- Capex-$618.0K
= Free Cash Flow-$68.9M

Analysis

FY2025 free cash flow is -$68.9M. FCF conversion is 76.0% of net income. Operating cash flow was -$68.3M, with capex of -$618.0K. The largest bridge item is Stock-Based Comp at $13.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
DEF 14ADEF 14A filingOct 23, 2026
DEFA14ADEFA14A filingOct 23, 2026
PRE 14APRE 14A filingOct 13, 2026

Does TNYA generate free cash flow?

Tenaya Therapeutics, Inc. (TNYA) generated -$68.88M of free cash flow in fiscal 2025.

How much operating cash flow does TNYA produce?

Operating cash flow was -$68.26M, before capital expenditures of $618,000.00.